Tandem Diabetes Care has announced the Tandem Choice technology access program, allowing eligible customers in the United States to purchase the Tandem Mobi System for $199.
The Tandem Mobi recently received clearance from the FDA to be used as part of an automated insulin delivery system. The limited launch is expected later this year, with general availability in early 2024.
This program gives customers the opportunity to experience the benefits of the Control-IQ technology while deciding which pump platform, either the t:slim X2 or the new Tandem Mobi, best suits their needs and preferences.
The Tandem Mobi offers smartphone control and new wearability options, giving people with diabetes more choices in customising their automated insulin delivery system.
Click here to read the original news story.